In vitro activity of ceftaroline against bacterial isolates causing skin and soft tissue and respiratory tract infections collected in Latin American countries, ATLAS program 2016-2020.

Autor: Mohamed N; Pfizer, Inc., New York, New York, USA., Valdez RR; Pfizer Latin America, Mexico., Fandiño C; Pfizer Andean Cluster, Santiago, Chile., Baudrit M; Pfizer Central America and Caribbean, San José, Costa Rica., Falci DR; School of Medicine, Pontifical Catholic University of Rio Grande do Sul, RS, Brazil., Murillo JDC; Infectious Diseases Department, Hospital Dr. Rafael Ángel Calderón Guardia, San José, Costa Rica; School of Medicine, Universidad de Costa Rica, San José, Costa Rica. Electronic address: jorge.chaverri@ucr.ac.cr.
Jazyk: angličtina
Zdroj: Journal of global antimicrobial resistance [J Glob Antimicrob Resist] 2024 Mar; Vol. 36, pp. 4-12. Date of Electronic Publication: 2023 Nov 26.
DOI: 10.1016/j.jgar.2023.11.006
Abstrakt: Objectives: Ceftaroline, a broad-spectrum cephalosporin, has activity against Gram-positive and several Gram-negative bacteria (GNB). This study aimed to evaluate the antimicrobial activity of ceftaroline and comparators against isolates causing skin and soft tissue infections (SSTIs) and respiratory tract infections (RTIs) collected in Latin America (LATAM) in 2016-2020 as part of the Antimicrobial Testing Leadership and Surveillance program (ATLAS).
Methods: Minimum inhibitory concentrations were determined using both Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria.
Results: Ceftaroline demonstrated potent activity against methicillin-susceptible Staphylococcus aureus (CLSI/EUCAST: MIC 90 0.25 mg/L; susceptibility 100%), whereas activity against methicillin-resistant S. aureus varied for SSTIs (MIC 90 1 mg/L; susceptibility 92.5%) and RTIs isolates (MIC 90 2 mg/L; susceptibility 72.9%) isolates. For Streptococcus pneumoniae, particularly penicillin-resistant isolates commonly causing respiratory infections, high ceftaroline activity (MIC 90 0.25 mg/L; susceptibility 100%/98.4%) was noted. All isolates of β-hemolytic streptococci were susceptible to ceftaroline (S. agalactiae: MIC 90 0.03 mg/L [SSTIs]; MIC 90 0.015 mg/L (RTIs); susceptibility 100%; S. pyogenes: MIC 90 0.008 mg/L; susceptibility 100%). Ceftaroline was highly active against Haemophilus influenzae, including β-lactamase positive isolates (MIC 90 0.06 mg/L; susceptibility 100%/85.7%). Ceftaroline demonstrated high activity against non-ESBL-producing GNB (E. coli: MIC 90 0.5 mg/L, susceptibility 91.9%; K. pneumoniae: MIC 90 0.25 mg/L, susceptibility 95.1%; K. oxytoca, MIC 90 0.5 mg/L; susceptibility 95.7%).
Conclusion: Ceftaroline was active against the recent collection of bacterial pathogens commonly causing SSTIs and RTIs in LATAM. Local and regional surveillance of antimicrobial resistance patterns are crucial to understand evolving resistance and guide treatment management.
(Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: